Hello, I am an expert writer for Daily Stock.
You must have had a long day monitoring the fast-paced movements of the pharmaceutical and biotechnology sector in the KOSDAQ market today.
Key Summary
[Image: /stdaily/uploads/202605/gen_6a0c1982a244e4.03951665.png]
The KOSDAQ index closed at 1084.36 as of May 19, 2026, showing a trend synchronized with the flow of global growth stocks.
Ahead of the upcoming ASCO 2026, the announcement of major clinical data by K-Bio companies is emerging as a key market event.
In particular, the clinical progress of major KOSDAQ bio companies such as LigaChem Biosciences, Abion, and ViGenCell is driving investor sentiment.
Now is the time that requires a selective approach toward companies with pipelines that have opened up the possibility of partnerships with global big pharma.
Current Situation Summary
As of the close on May 19, 2026, the KOSPI index recorded 7271.66, and the KOSDAQ index recorded 1084.36.
On the same day, the NASDAQ closed at 26090.73, and the KRW/USD exchange rate remains at a somewhat high level of 1507.30 won.
■ Daily Stock's Proprietary Fear & Greed Index (0~100, 0=Extreme Fear, 100=Extreme Greed):
- KOSPI Fear/Greed: Current Neutral (55.4), 1 week ago Greed (64.6), 1 month ago Neutral (58.3), 3 months ago Neutral (57.1)
- NASDAQ Fear/Greed: Current Greed (62.7), 1 week ago Greed (65.1), 1 month ago Greed (68.6), 3 months ago Greed (69.7)
Despite the ongoing burden of the exchange rate in the 1500 won range, foreign program buying inflows defended the downside of growth stocks within the KOSDAQ 150.
A distinct differentiation pattern is observed, with supply and demand concentrating on the KOSDAQ 150 large-cap bio and secondary battery sectors compared to the KOSDAQ Small index.
Financial Analysis
[Image: /stdaily/uploads/202605/gen_6a0c1997852df6.04799670.png]
By nature, KOSDAQ bio companies focused on new drug development mostly record operating deficits due to massive research and development (R&D) expenses.
As a result, investors should focus on the cash assets held and the inflow of milestones from licensing out (L/O) rather than the simple profit margin of the company.
For instance, LigaChem Biosciences, which recently received an Investigational New Drug (IND) Phase 1/2 approval from the US FDA, has secured ample financial buffering capacity based on its accumulated technology export contracts.
Abion and ViGenCell are also drawing attention to whether their achievements on global stages, such as the upcoming ASCO, can serve as a catalyst for generating large-scale profits in the future.
Therefore, it is necessary to view the late-stage clinical trial entry rate of individual pipelines and the cost-sharing structure with big pharma as an extension of financial indicators.
Valuation
Using traditional PER (Price-to-Earnings Ratio) metrics makes it difficult to properly evaluate the value of new drug development companies that do not generate immediate profits.
Instead, alternative indicators such as risk-adjusted Net Present Value (r-NPV) for each drug development stage, PSR (Price-to-Sales Ratio), and EV/EBITDA are widely utilized.
Recently, the KOSDAQ market has shown a trend of granting higher premiums to 'data integrity' and 'superiority over competing drugs' rather than just the simple number of pipelines.
Analysts also suggest that companies possessing platform technologies aligned with global trends, such as Antibody-Drug Conjugates (ADCs) or immune cell therapies, still hold valuation appeal compared to their global peers.
However, investors must always be cautious that unexpected variables, such as clinical delays or preemptive approvals of competing drugs, could cause the valuation gap to narrow rapidly.
Expert & Institutional Analysis
Stock market experts analyze that May and June are the traditional peak seasons for the pharmaceutical and biotechnology sector, as global conference schedules are concentrated during this period.
This is because major data presentation events are lined up one after another, starting with the American Society of Clinical Oncology (ASCO) at the end of May, followed by the European Association for the Study of the Liver (EASL) and the American Diabetes Association (ADA) in June.
According to major institutional reports, this year is considered a 'year of selection' where only companies that prove themselves with tangible clinical data, rather than vague expectation themes, will survive.
Whether a company holds late-stage clinical assets that big pharma would actively consider adopting is expected to serve as a key variable for share price revaluation.
Consequently, program inflows from institutional and foreign investors are increasingly trending toward companies confirmed to have abstracts accepted or oral presentations scheduled at global conferences.
| Company | Pipeline | Indication | Major Conference/Event | Clinical Status & 2026 Expectations |
|---|---|---|---|---|
| LigaChem Biosciences | LCB02A | Solid Tumors | FDA Phase 1/2 Approval (5/14) | Claudin 18.2 ADC, Target to commence first patient dosing in Q3 |
| Abion | Vabametkib (ABN401) | NSCLC | ASCO 2026 | Announcement of global Phase 2 BICR results, confirmed ORR over 50% |
| ViGenCell | VT-EBV-N | NK/T-cell Lymphoma | ASCO 2026 | Assigned to formal oral presentation session, a first for a domestic cell therapy |
| GI Innovation | GI-101A | Solid Tumors | ASCO 2026 | Assigned to Rapid Oral presentation, verifying combination therapy synergy |
| HLB | Rivoceranib | Liver Cancer 1st-line | FDA PDUFA Schedule | Awaiting new drug approval, full-scale global marketing if successful |
Risk Factors
[Image: /stdaily/uploads/202605/gen_6a0c19b0e8ec43.97918794.png]
The biggest macroeconomic risks suppressing the bio sector are the high exchange rate exceeding the 1500 won range and the higher-for-longer-than-expected interest rate environment.
If interest rates remain high, funding costs increase, which can amplify concerns over shareholder value dilution due to paid-in capital increases or convertible bond (CB) issuances for additional clinical trials.
Furthermore, as the saying goes, "buy the rumor, sell the news," the possibility of massive short-term profit-taking sales immediately after the conference announcements cannot be ruled out.
If the disclosed clinical data fail to meet the market's high expectations, coupled with the low-liquidity market conditions, there is a distinct risk of experiencing double-digit volatility in a single day.
Investment Perspective
Current investments in KOSDAQ pharmaceuticals and bios must be strategized strictly based on the clear timeline of the global clinical calendar.
It is a priority to conservatively check whether the data of the companies participating in the conferences are meaningful results that could lead to actual technology exports.
Rather than recklessly chasing purchases during short-term price surges, one must objectively evaluate the comparative advantage of the company's pipeline value among KOSDAQ large-cap stocks.
A scenario approaching with split purchases utilizing the timing when the quality of data is officially confirmed and market supply and demand stabilize could be an alternative.
Frequently Asked Questions
- When is ASCO 2026 held?
The American Society of Clinical Oncology (ASCO) 2026, the world's largest cancer conference, will be held in Chicago, USA, from May 29 to June 2, local time.
During this period, major pharmaceutical companies and bio ventures worldwide will present a massive amount of the latest clinical data related to new anticancer drugs and engage in academic exchanges.
- What is the recent major clinical progress of LigaChem Biosciences?
On May 14, 2026, its self-developed Claudin 18.2-targeted Antibody-Drug Conjugate (ADC) 'LCB02A' obtained Phase 1/2 Investigational New Drug (IND) approval from the US FDA.
With this as a starting point, the company plans to accelerate multinational clinical procedures with the goal of dosing the first patient within the third quarter of this year.
- What is the core of the data Abion will disclose at ASCO 2026?
Abion plans to detail additional global Phase 2 data for its c-MET targeted anticancer drug 'vabametkib'.
The confirmation of an excellent Objective Response Rate (ORR) of over 50% in the entire patient group and a superior safety profile is drawing high expectations from the market.
- Why is ViGenCell's presentation drawing attention in the KOSDAQ bio industry?
ViGenCell will present Phase 2 results of its in-development immune cell therapy 'VT-EBV-N' at a formal oral presentation session at ASCO.
It carries significant symbolic meaning as this is the first time clinical data for a cell therapy independently developed by a domestic biotech has taken the stage for a general oral presentation at ASCO.
- Why do high-interest rate and high-exchange rate environments act unfavorably on bio stock prices?
Bio companies are representative high-risk, high-return growth stocks that expect large future profits by investing massive capital over a long period.
High interest rates increase the discount rate on future value and sharply raise the interest burden during external fundraising, delivering a direct and continuous hit to valuations.